CVMP opinions on veterinary medicinal products

Under Regulation (EU) 2019/6

The Committee adopted by consensus a positive opinion for a marketing authorisation application for Eluracat (capromorelin tartrate), from Elanco GmbH, a new product for body weight gain in cats experiencing poor appetite or unintended weight loss resulting from chronic medical conditions.

The Committee adopted by consensus positive opinions for variations requiring assessment concerning quality-related changes for:

• Chanaxin
• Hiprabovis IBR Marker Live
• Forceris (grouped)
• Librela
• Prevexxion RN, Prevexxion RN+HVT+IBD (worksharing procedure)
• Purevax RCP FeLV, Purevax RCPCh FeLV, Purevax RC, Purevax RCP, Purevax RCPCh (worksharing procedure)
• Reconcile
• Strangvac
• Versican Plus DHPPi/L4R, Versican Plus Pi/L4R (worksharing procedure)
• Ypozane

 The Committee adopted by consensus positive opinions for variations requiring assessment to align the product information with version 9.0 of the QRD template for:

• Canigen…